INCY Chart

1 Month

	Date	Diff
	2023-11-30	+1.78 %
Innovent Biologics has been upgraded to an 'A' rating according to Morgan Stanley Capital International's (MSCI) latest ESG rating, which reflects the capital market's recognition of Innovent's progress in ESG governance and sustainability, leading to an increase in the stock price.
	2023-11-15	+0.75 %
The article discusses the financial results of MorphoSys AG, which owns the Monjuvi drug, and provides updates on its clinical trials and product sales. The stock price of Incyte (INCY) went up as a result of positive sales and the potential for improvement in the company's pipeline.
	2023-11-08	-1.21 %
Jean-Jacques "JJ" Bienaimé, a biotechnology and pharmaceutical executive, has been appointed to the Board of Directors of Immunome, a biotechnology company focused on developing targeted cancer therapies. Bienaimé's experience in building biotech companies and his commitment to improving the lives of cancer patients will be valuable as Immunome advances its pipeline of potential therapies. Last night, Incyte Corp., where Bienaimé currently serves on the Board of Directors, saw its stock go down by 1.21%. The reason for the decline in Incyte's stock is not mentioned in the article.
	2023-10-31	+3.39 %
Incyte (INCY) stock went up by 3.39% following the release of its third quarter financial results, which showed total revenues of $919 million, a 12% year-over-year increase, driven by strong performance of its drugs Jakafi (ruxolitinib) and Opzelura (ruxolitinib cream) due to increased patient demand and enhanced payer coverage.
	2023-10-26	+0.04 %
Incyte (INCY) stock went up by 0.04% last night. The article does not provide a direct explanation for why the stock went up; it only discusses the upcoming IPO of Cargo Therapeutics, Inc. and their plans to develop drug candidates for treating large B cell lymphoma cancer. The article announces that Insmed Incorporated has been ranked as the number one employer in Science's 2023 Top Employers Survey, leading companies such as Incyte, Alnylam, Regeneron, and Syngenta Group. The reason for the increase in Incyte's stock price is not mentioned in the article.
	2023-10-20	-0.92 %
Incyte (INCY) stock went down by 0.92% due to the impact of rising bond yields and shifting healthcare policies, which weighed on biotech stocks and the stock market in general.
	2023-10-18	-0.65 %
The article does not provide any information about why Incyte (INCY) stock went down. It only states that the company will be presenting at investor conferences in November.
	2023-10-16	+0.03 %
The article announces that Knight Therapeutics Inc. has received pricing approval for its drug Minjuvi® in Brazil, which has led to an increase in Incyte stock as Incyte has a distribution agreement with Knight for Minjuvi® in Latin America.
	2023-10-13	+1.84 %
The article discusses the expansion of results from the Phase 3 TRuE-AD3 trial evaluating the safety and efficacy of Incyte's ruxolitinib cream in children with atopic dermatitis (AD), and states that the stock went up by 1.84% following the announcement. The stock goes up because the data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 reinforce the strong safety and efficacy profile of the cream, indicating its potential to treat younger age groups and addressing a significant medical need for a nonsteroidal topical treatment for AD in children.
	2023-10-11	-0.49 %
Incyte (Nasdaq:INCY) announced positive 52-week data from a Phase 2b clinical trial for povorcitinib, an oral JAK1 inhibitor, in patients with extensive nonsegmental vitiligo, which showed substantial total body and facial repigmentation; the reason for the stock going down is not mentioned in the article. Incyte (Nasdaq:INCY) announced new results from a pooled analysis of long-term extension (LTE) data from the TRuE-V program, which showed improved repigmentation in patients with nonsegmental vitiligo who continued treatment with Opzelura cream 1.5% for up to two years; the stock may have gone down due to other factors unrelated to this news. The article announces Incyte's partnership with Mandy Moore on an educational initiative about atopic dermatitis and its treatment, which may have caused the stock to go down due to unrelated factors in the market.
	2023-10-10	+0.99 %
Incyte (INCY) stock went up by 0.99% following the announcement that Knight Therapeutics, Inc., Incyte's partner, has submitted a marketing authorization application for pemigatinib, a treatment for cholangiocarcinoma, to the Brazilian health regulatory agency. Incyte (INCY) stock was up 0.99% last night, and the stock may have gone up due to the announcement of the company's scheduled third quarter financial results conference call and webcast on October 31, 2023.
	2023-09-29	-1.43 %
Incyte (Nasdaq:INCY) stock went down by -1.43% last night, but the article does not provide a specific reason for the decline.
	2023-09-20	-0.38 %
The article discusses the 13 best beaten down stocks to buy now, including Incyte Corporation (NASDAQ:INCY). The reason for Incyte's stock going down is not mentioned in the article.
	2023-09-19	+1.83 %
The article discusses a new cancer-focused venture capital firm called Yosemite, led by Reed Jobs, the son of Steve Jobs, which has received $200 million in funding and aims to develop treatments for pancreatic cancer, a market expected to exceed $7.4 billion by 2032, leading to an increase in stock prices for companies involved in pancreatic cancer research, such as Incyte Corporation (NASDAQ:INCY).
	2023-09-18	-4.86 %
Incyte (INCY) stock went down by 4.86% after the FDA approved a competing treatment for blood cancer from GlaxoSmithKline (GSK). Incyte (INCY) stock fell 5% after the FDA approved a competing treatment for blood cancer from GSK (GSK), causing investors to sell off shares. The article discusses the recent decline in Incyte Corp (NASDAQ:INCY) stock, which experienced a daily loss of -5.12% and a 3-month loss of -5.84%. The article suggests that the stock may be significantly undervalued based on a valuation analysis. The analysis considers factors such as the stock price compared to the GF Value, which measures a stock's intrinsic value. However, it is not specified why exactly the stock went down in value.
	2023-09-13	-1.76 %
Incyte (INCY) stock went down last night, and the reason for the decrease is not mentioned in the article.
	2023-09-12	-0.28 %
The article is about Incyte (INCY) stock, which went down by 0.28% last night. The reason for the stock decline is not mentioned in the article.
	2023-08-22	-0.14 %
The article does not provide information on why Incyte (INCY) stock went down by 0.14% last night.
	2023-08-14	-1.05 %
Incyte's (NASDAQ:INCY) stock went down by 1.05% last night, and while the company's return on equity (ROE) does not compare favorably to the industry average, its net income growth over the past five years has been exceptional, indicating other positive factors influencing its earnings growth.
	2023-08-07	+2.01 %
Merus N.V., a clinical-stage oncology company, announced that its drug petosemtamab has been granted Fast Track Designation for the treatment of head and neck squamous cell carcinoma, which has led to increased interest in Incyte stock. Incyte (INCY) stock went up by 2.01% following the announcement that petosemtamab, a drug being developed by Merus N.V., was granted Fast Track Designation for the treatment of recurrent or metastatic head and neck squamous cell carcinoma; furthermore, Merus plans to initiate a phase 3 trial of petosemtamab monotherapy in mid-2024, and Zeno, another drug being developed by Merus, was granted Breakthrough Therapy Designations in NRG1 fusion non-small cell lung and pancreatic cancer.
	2023-08-01	-0.05 %
The article mentions that Incyte (INCY) stock went down by -0.05% last night. The reason for the decline is not mentioned in the given information. The article mentions that the Incyte (INCY) stock went down by 0.05% last night, but it does not provide a specific reason for the decrease in value.
	2023-07-19	+1.98 %
The article explains that healthcare stocks have been declining as market conditions changed, but Incyte (INCY) stock, along with other selected healthcare companies, has the potential for gains because of its strong cancer pipeline and promising long-term prospects. The reason Incyte stock went up last night is not specifically mentioned in the article.
	2023-07-11	+1.53 %
Incyte Corp's stock (INCY) went up 1.53% after the company announced that its cream, Opzelura, met the primary goal in a late-stage study for treating a type of skin condition in children between the ages of two to twelve. The article announces that Incyte (Nasdaq:INCY) has scheduled its second quarter financial results conference call and webcast, leading to a 1.53% increase in their stock.